Concert Pharmaceuticals Return on Equity

Concert Pharmaceuticals (CNCE) currently reports a ROE of -49.86%. That is below the Healthcare sector average of 20.86%. Use the charts on this page to explore Concert Pharmaceuticals's ROE history and peer comparisons.

Concert Pharmaceuticals's ROE of -49.86% is lower than the Healthcare sector average of 20.86%. That is roughly 339.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Concert Pharmaceuticals's current -49.86% should be judged against Healthcare norms (sector average: 20.86%) and against CNCE's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -49.86%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 20.86%. From there, open related valuation or income-statement pages for Concert Pharmaceuticals, and consider following CNCE for alerts when major investors trade the stock.

Concert Pharmaceuticals is classified in the Healthcare sector. On ROE, it currently shows -49.86% versus a sector average near 20.86%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CNCE with unrelated industries.